S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.36 (+0.52%)
MSFT   214.37 (-0.85%)
FB   288.71 (+0.75%)
GOOGL   1,828.94 (+1.87%)
AMZN   3,217.50 (-0.08%)
TSLA   561.42 (-3.99%)
NVDA   543.67 (+1.51%)
BABA   261.76 (-0.85%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.45 (+2.04%)
AMD   94.26 (+1.76%)
T   28.94 (+0.24%)
NIO   46.50 (+2.51%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   504.18 (-0.08%)
BA   218.96 (+2.79%)
GILD   61.23 (+0.18%)
DIS   152.47 (+2.03%)
S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.36 (+0.52%)
MSFT   214.37 (-0.85%)
FB   288.71 (+0.75%)
GOOGL   1,828.94 (+1.87%)
AMZN   3,217.50 (-0.08%)
TSLA   561.42 (-3.99%)
NVDA   543.67 (+1.51%)
BABA   261.76 (-0.85%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.45 (+2.04%)
AMD   94.26 (+1.76%)
T   28.94 (+0.24%)
NIO   46.50 (+2.51%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   504.18 (-0.08%)
BA   218.96 (+2.79%)
GILD   61.23 (+0.18%)
DIS   152.47 (+2.03%)
S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.36 (+0.52%)
MSFT   214.37 (-0.85%)
FB   288.71 (+0.75%)
GOOGL   1,828.94 (+1.87%)
AMZN   3,217.50 (-0.08%)
TSLA   561.42 (-3.99%)
NVDA   543.67 (+1.51%)
BABA   261.76 (-0.85%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.45 (+2.04%)
AMD   94.26 (+1.76%)
T   28.94 (+0.24%)
NIO   46.50 (+2.51%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   504.18 (-0.08%)
BA   218.96 (+2.79%)
GILD   61.23 (+0.18%)
DIS   152.47 (+2.03%)
S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.36 (+0.52%)
MSFT   214.37 (-0.85%)
FB   288.71 (+0.75%)
GOOGL   1,828.94 (+1.87%)
AMZN   3,217.50 (-0.08%)
TSLA   561.42 (-3.99%)
NVDA   543.67 (+1.51%)
BABA   261.76 (-0.85%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.45 (+2.04%)
AMD   94.26 (+1.76%)
T   28.94 (+0.24%)
NIO   46.50 (+2.51%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   504.18 (-0.08%)
BA   218.96 (+2.79%)
GILD   61.23 (+0.18%)
DIS   152.47 (+2.03%)
Log in
ARCA:OCX

OncoCyte Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.93 million shs
Market Capitalization$99.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.29 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone949 409 7600
Employees33

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-22,430,000.00

Miscellaneous

Market Cap$99.53 million
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (ARCA:OCX) Frequently Asked Questions

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of OncoCyte's key competitors?

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 60, Pay $312.5k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg Ph.D., Chief Scientific Officer
  • Mr. William Annett, Advisor (Age 66, Pay $673.33k)
  • Mr. Albert P. Parker II, COO & Sec.
  • Mr. Tony T. Kalajian CPA, M.B.A., Sr. VP & Chief Accounting Officer
  • Ms. Padma Sundar, Sr. VP of Commercial
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Medical Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 67)
  • Ms. Sara Riordan, Director of Medical Education

What is OncoCyte's stock symbol?

OncoCyte trades on the ARCA under the ticker symbol "OCX."

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $0.00. The company earns $-22,430,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. OncoCyte employs 33 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The company can be reached via phone at 949 409 7600 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.